

VBC Release Highlights

October 6, 2023

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

The dashboard has also been updated to reflect the below refinement(s) for:

Measure	Description	
<p>MIPS #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan</p>	<p>2023 Measure Specification Update to include:</p> <ul style="list-style-type: none"> • This measure is only looking for a documented BMI and follow-up plan to take place during the encounter or during the measurement period. The previous 12 months for documentation of the BMI and follow-up plan have been removed for 2023. • Denominator Exclusion is looking for pregnant patients, hospice patients, and patients receiving palliative care at any time during the measurement period. 	<p>Practices should see a shift in the Numerator and Denominator.</p>

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

NOTE: Table continues on the next page.

Measure	Description
MIPS Quality Measures Dashboard	
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Tobacco Screening and Cessation
#236	Controlling High Blood Pressure
#374	Closing the Referral Loop
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#453	Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 147 Days of Life (Inverse Measure)

Measure	Description
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center